Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001.

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Abstract Text:

JoAnne Robbins,Susan Langmore,Jacqueline A Hind,Martin Erlichman,

Swallowing problems (dysphagia) can occur at any age but are most prevalent in elderly individuals and are a growing healthcare concern as the geriatric population expands. Without effective diagnosis and treatment, dysphagia may lead to serious medical conditions such as pneumonia, dehydration, and malnutrition. Experts in the field of dysphagia met on August 21, 2001, in Rockville, Maryland, to respond to this heightened healthcare need and to determine the course of dysphagia research. Presentations at the meeting included epidemiological data, geriatric-specific issues, diagnostic techniques, risk factors for pneumonia, and recent relevant trials. The experts identified outstanding issues in dysphagia research, such as study design, population selection, and the standardization of diagnostic and treatment protocols. They designed a clinical trial that represents what they deem is one of the greatest needs in dysphagia research, providing a critical springboard for research endeavors with far-reaching implications.

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Publishing Authors By Initials

J Robbins,S Langmore,JA Hind,M Erlichman,

For similar animals: chordata: vertebrates: mammals: primates: haplorhini: catarrhini: hominidae: humans research abstracts see: animals: chordata: vertebrates: mammals: primates: haplorhini: catarrhini: hominidae: humans research

PUBMED ID PMID:

MEDLINE DATE:

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of rehabilitation research and development

VOLUME: 39

Page Numbers: 543-8

Journal Abbreviation:

ISSN: 0748-7711

DAY: 3

MONTH: 12

YEAR: 2007

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8410047

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Keywords Mesh Terms:

KEYWORDS: Humans

MESH TERMS: therapy

Chemical & Substance for Abstract: Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001.

AFFILIATION: William S. Middleton Memorial Veterans Hospital, Geriatric Research, Education and Clinical Center, 2500 Overlook Terrace, Madison, WI 53705, USA. jrobbin2@facstaff.wisc.edu

Country: United States

AGENCY: United States NIDCD

GRANT: U01 DC0326

ACRONYM: DC

MEDLINETA: J Rehabil Res Dev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001 Related Publications

• A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
• An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
• Cisplatin abrogates the geldanamycin-induced heat shock response.
• Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001.
• HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
• P-glycoprotein-mediated resistance to hsp90-directed therapy is eclipsed by the heat shock response.
• Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
• Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.